CMLHope.Com
A Worldwide Support Network For Chronic Myelogenous Leukemia
Posted by rob on June 15, 2008 under Uncategorized | Be the First to Comment
PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.
In Vitro Induction of a Dendritic Cell Phenotype in Primary Human Acute Myelogenous Leukemia (AML) Blasts Alters the Chemokine Release Profile and Increases the Levels of T Cell Chemotactic CCL17 and CCL22.
You must be logged in to post a comment.
Add A Comment
You must be logged in to post a comment.